MCM
BIB icon

MAI Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

MAI Capital Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.4K Hold
250
– – ﹤0.01% 2775
2025
Q4 		$19.9K Hold
250
– – ﹤0.01% 2515
2025
Q3 		$14.9K Hold
250
– – ﹤0.01% 2547
2025
Q2 		$11.5K Hold
250
– – ﹤0.01% 2653
2025
Q1 		$12K Hold
250
– – ﹤0.01% 2413
2024
Q4 		$12.7K Buy
+250
New +$14.8K ﹤0.01% 2410

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

MAI Capital Management's BIB Position: Q1 2026 in Review

MAI Capital Management held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q1 2026 at 250 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2775.

MAI Capital Management first reported a position in BIB in Q4 2024 and has held it in 6 quarters since. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • MAI Capital Management held 250 shares of ProShares Ultra NASDAQ Biotechnology worth $20.4K as of Q1 2026.
  • MAI Capital Management left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #2775 holding.
  • MAI Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2024 and has held it in 6 quarters since.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.